Skip to main content

Advertisement

SpringerLink
Log in

CHECKPOINT INHIBITION

Checkpoint inhibition: NK cells enter the scene

  • News & Views
  • Published:

From Nature Immunology

View current issue Submit your manuscript

Tumor-associated natural killer cells have elevated expression of the checkpoint inhibitory receptor TIGIT. Monoclonal antibody–mediated blockade targeting TIGIT unleashes the anti-tumor activity of both natural killer cells and T cells in preclinical mouse models and efficiently delays tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Mode of action of the blockade of TIGIT in anti-tumor immunity.

Marina Corral Spence/Springer Nature

References

  1. Zhang, Q. et al. Nat. Immunol. https://doi.org/10.1038/s41590-018-0132-0 (2018)

  2. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. & Smyth, M. J. Clin. Cancer Res. 22, 5183–5188 (2016).

    Article  PubMed  CAS  Google Scholar 

  3. Stanietsky, N. et al. Proc. Natl Acad. Sci. USA 106, 17858–17863 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Johnston, R. J. et al. Cancer Cell 26, 923–937 (2014).

    Article  PubMed  CAS  Google Scholar 

  5. Yu, X. et al. Nat. Immunol. 10, 48–57 (2009).

    Article  PubMed  CAS  Google Scholar 

  6. Cerwenka, A. & Lanier, L. L. Nat. Rev. Immunol. 16, 112–123 (2016).

    Article  PubMed  CAS  Google Scholar 

  7. Chiossone, L., Vienne, M., Kerdiles, Y. M. & Vivier, E. Semin. Immunol. 31, 55–63 (2017).

    Article  PubMed  CAS  Google Scholar 

  8. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. & Cerwenka, A. J. Immunol. 192, 4184–4191 (2014).

    Article  PubMed  CAS  Google Scholar 

  9. Della Chiesa, M. et al. Front. Immunol 7, 351 (2016).

    PubMed  PubMed Central  Google Scholar 

  10. Stojanovic, A., Correia, M. P. & Cerwenka, A. Cancer Microenviron 6, 135–146 (2013).

    Article  PubMed  CAS  Google Scholar 

  11. Blake, S. J. et al. Cancer Discov 6, 446–459 (2016).

    Article  PubMed  CAS  Google Scholar 

  12. Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & van Hall, T. Curr. Opin. Immunol. 39, 44–51 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Biomedicine and Medical Technology, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany

    Ana Stojanovic & Adelheid Cerwenka

  2. European Center for Angioscience, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany

    Adelheid Cerwenka

Authors
  1. Ana Stojanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adelheid Cerwenka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adelheid Cerwenka.

Ethics declarations

Competing interests

A.C. is a member of the scientific advisory board of Dragonfly Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stojanovic, A., Cerwenka, A. Checkpoint inhibition: NK cells enter the scene. Nat Immunol 19, 650–652 (2018). https://doi.org/10.1038/s41590-018-0142-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-018-0142-y

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation